FDA’s interest in fostering innovation in OTC switches may be the most significant factor working in favor of Lipitor as Pfizer Inc. maneuvers toward a possible attempt to bring the statin to nonprescription status.
Research recommendations and regulatory changes in recent years also contribute to an environment likely to be more open to a statin switch than previous bids faced, experts note.